Search details
1.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Breast Cancer Res Treat
; 197(2): 319-331, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36401732
2.
GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
Drug Metab Dispos
; 47(9): 966-973, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31266752
3.
Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.
Pharm Res
; 35(2): 37, 2018 Jan 29.
Article
in English
| MEDLINE | ID: mdl-29380076
4.
Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Pharm Res
; 35(12): 233, 2018 Oct 15.
Article
in English
| MEDLINE | ID: mdl-30324422
5.
Correction to: Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Pharm Res
; 35(12): 244, 2018 10 26.
Article
in English
| MEDLINE | ID: mdl-30367284
6.
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.
CPT Pharmacometrics Syst Pharmacol
; 13(4): 660-672, 2024 04.
Article
in English
| MEDLINE | ID: mdl-38481038
7.
Impact of P-gp inhibition on systemic exposure of pralsetinib and dosing considerations.
Clin Transl Sci
; 17(6): e13818, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38807449
8.
Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics.
Pharmaceutics
; 16(4)2024 Apr 20.
Article
in English
| MEDLINE | ID: mdl-38675225
9.
Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer.
J Clin Pharmacol
; 64(6): 685-696, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38337106
10.
A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.
Biopharm Drug Dispos
; 34(3): 141-54, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23225350
11.
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
Clin Cancer Res
; 29(15): 2781-2790, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37261814
12.
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.
Target Oncol
; 17(3): 283-293, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35715627
13.
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Ann Clin Transl Neurol
; 9(1): 50-66, 2022 01.
Article
in English
| MEDLINE | ID: mdl-35014217
14.
Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
Clin Pharmacol Drug Dev
; 10(2): 144-152, 2021 02.
Article
in English
| MEDLINE | ID: mdl-32696585
15.
The involvement of intracellular calcium in the MCT-mediated uptake of lactic acid by HeLa cells.
Mol Pharm
; 7(1): 169-76, 2010 Feb 01.
Article
in English
| MEDLINE | ID: mdl-19905008
16.
Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective.
Clin Pharmacol Ther
; 2024 Mar 27.
Article
in English
| MEDLINE | ID: mdl-38536001
17.
A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.
Bioorg Med Chem Lett
; 18(21): 5763-5, 2008 Nov 01.
Article
in English
| MEDLINE | ID: mdl-18842409
18.
Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.
Bioorg Med Chem Lett
; 18(23): 6236-9, 2008 Dec 01.
Article
in English
| MEDLINE | ID: mdl-18926699
19.
Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.
J Clin Pharmacol
; 58(11): 1427-1435, 2018 11.
Article
in English
| MEDLINE | ID: mdl-29786857
20.
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Cancer Chemother Pharmacol
; 80(1): 29-36, 2017 Jul.
Article
in English
| MEDLINE | ID: mdl-28523596